Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Hertz

Showing results (311-320 of 368) with videos related to

Pageof 37
Sort By:
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 16, 2004
Surrogate markers and risk factors for chronic lung allograft dysfunctionMichael E Bowdish, Selim M Arcasoy, Jessie S Wilt, et al.
Breast Cancer Research and Treatment|July 22, 2017
CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based studyD L Hertz, K M Kidwell, S G Hilsenbeck, et al.
Molecular Oncology|August 16, 2015
Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analysesDaniel L Hertz, Kelley M Kidwell, Jacklyn N Thibert, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 6, 2026
Serum neurofilament light chain (sNFL) as a predictive biomarker for Chemotherapy-induced peripheral neurotoxicity (CIPN): consideration of current evidence, validation steps, and barriers to CIPN biomarker implementation in clinical practice-a narrative reviewPaola Alberti, Sara Faithfull, Andreas A Argyriou, et al.
Frontiers in Genetics|July 2, 2021
Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast CancerDaniel L Hertz, Karen Lisa Smith, Yuhua Zong, et al.
Pharmacogenetics and Genomics|June 7, 2021
Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activityDaniel L Hertz, Julie A Douglas, Kelley M Kidwell, et al.
Oral Diseases|December 4, 2020
Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancerCatherine Van Poznak, Evan L Reynolds, Cherry L Estilo, et al.
Breast Cancer Research and Treatment|June 24, 2017
Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patientsDaniel L Hertz, Kelly A Speth, Kelley M Kidwell, et al.
Neurology|April 1, 1997
Noninvasive assessment of language dominance in children and adolescents with functional MRI: a preliminary studyL Hertz-Pannier, W D Gaillard, S H Mott, et al.
Clinical Pharmacology and Therapeutics|May 10, 2023
Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines Who are Suspected DPYD Variant Carriers Based on a Genetic Data RepositoryAmy L Pasternak, Robinson Seda, Joseph Lipa, et al.
Pageof 37

Showing results (311-320 of 368) with videos related to

Sort By:
Pageof 37
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 16, 2004
Surrogate markers and risk factors for chronic lung allograft dysfunctionMichael E Bowdish, Selim M Arcasoy, Jessie S Wilt, et al.
Breast Cancer Research and Treatment|July 22, 2017
CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based studyD L Hertz, K M Kidwell, S G Hilsenbeck, et al.
Molecular Oncology|August 16, 2015
Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analysesDaniel L Hertz, Kelley M Kidwell, Jacklyn N Thibert, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 6, 2026
Serum neurofilament light chain (sNFL) as a predictive biomarker for Chemotherapy-induced peripheral neurotoxicity (CIPN): consideration of current evidence, validation steps, and barriers to CIPN biomarker implementation in clinical practice-a narrative reviewPaola Alberti, Sara Faithfull, Andreas A Argyriou, et al.
Frontiers in Genetics|July 2, 2021
Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast CancerDaniel L Hertz, Karen Lisa Smith, Yuhua Zong, et al.
Pharmacogenetics and Genomics|June 7, 2021
Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activityDaniel L Hertz, Julie A Douglas, Kelley M Kidwell, et al.
Oral Diseases|December 4, 2020
Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancerCatherine Van Poznak, Evan L Reynolds, Cherry L Estilo, et al.
Breast Cancer Research and Treatment|June 24, 2017
Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patientsDaniel L Hertz, Kelly A Speth, Kelley M Kidwell, et al.
Neurology|April 1, 1997
Noninvasive assessment of language dominance in children and adolescents with functional MRI: a preliminary studyL Hertz-Pannier, W D Gaillard, S H Mott, et al.
Clinical Pharmacology and Therapeutics|May 10, 2023
Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines Who are Suspected DPYD Variant Carriers Based on a Genetic Data RepositoryAmy L Pasternak, Robinson Seda, Joseph Lipa, et al.
Pageof 37